Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Kaken

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Kaken's Japan sales performance.

AZ, Daiichi Sankyo reveal new TNBC data for next-gen antibody drug conjugate

AZ, Daiichi Sankyo reveal new TNBC data for next-gen antibody drug conjugate Both companies will jointly develop and commercialise datopotamab deruxtecan worldwide, apart from in Japan where Daiichi will retain exclusive rights.

Q&A: Amar Urhekar

Q&A: Amar Urhekar We worked together at McCann in Japan. Just before his 30th birthday, he was diagnosed with ALS.

BeiGene, Novartis’s PD-1 inhibitor tislelizumab hits the mark in second- or third-line NSCLC

BeiGene, Novartis’s PD-1 inhibitor tislelizumab hits the mark in second- or third-line NSCLC As part of that agreement, Novartis gained development and commercialisation rights to tislelizumab in the US, Canada, Mexico, the EU, UK, Norway, Switzerland, Iceland, Liechtenstein, Russia and Japan for an upfront

A new era for UK-Japanese scientific research relations

A new era for UK-Japanese scientific research relations Japan’s healthcare needs. Japan’s healthcare economy has evolved immensely since WWII. ... Historically, Japan has struggled to recruit patients and conduct trials within its domestic population.

Amgen adds to oncology pipeline with $1.9bn Five Prime Therapeutics acquisition

Amgen adds to oncology pipeline with $1.9bn Five Prime Therapeutics acquisition The company said its would leverage its presence in Japan and other Asia-Pacific markets to maximise the potential of bemarituzumab in the gastric cancer market.

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

Personalised medicine: driving a need for greater diversity in clinical trials
Kate Shaw, Innovative Trials' Founder & CEO, investigates one of the biggest challenges facing clinical research today....
Congresses and conferences
Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
With the pandemic having dimmed the lights on pharma conferences, their virtual and hybrid replacements have grasped the opportunity and are here to stay...
Cervical Cancer Prevention Month
In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...